Doripenem versus bacteria: An emerging battleground

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 482-492

  Shakil, S ^a   Danishuddin, M ^a   Khan, Asad U ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Antibiotic armory; Antipseudomonals; Doripenem; Multidrug resistance

Indexed keywords

BETA LACTAMASE; CILASTATIN; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PROBENECID; VALPROIC ACID; CARBAPENEM DERIVATIVE;

ANAPHYLAXIS; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL PRACTICE; DIARRHEA; DRUG COST; DRUG STABILITY; EMPIRICISM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; MYCOSIS; NAUSEA; PHLEBITIS; PRESCRIPTION; RASH; REVIEW; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THRUSH; TOXIC EPIDERMAL NECROLYSIS; VULVITIS; ANIMAL; BACTERIUM; CHEMISTRY; DRUG EFFECT;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; CARBAPENEMS; HUMANS;

EID: 75549085436     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.482     Document Type: Review

References (26)

1. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in vstud. Crit Care Mod 9008: 36: 1089-1096.
2. Davies TA, Shang W, Bush K et al. Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin binding domains of pbpla, pbp2b and pbp2x. J Antimicrob Chermother 9008; 61: 751-753.
3. Poulakou G, Giamarellou H, Doripenem: an expected arrival in the treatment of infections caused by multidrug resistant G negative pathogens. Expert Opin Investig Drugs 2008; 17: 749-771.
4. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drug 2007; 67: 1027-1052.
5. Iso Y, Irie T, Nishino Y et al. A novel 1β-methylcarbapenem antibiotic, S-4661: synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1β-methlycarbapenems. J Antibiot 1996; 49: 199-209.
6. Jones RN, Huynh HK, Biedenbach DJ et al. Doripenem (S-4661). a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluation. J Antimicrob Chemother 2004; 54: 144-154.
7. Dalhoff A. Janjic N, Echols R. Redefining penems. Biochem Pharmacol 2006; 71: 1085-1095.
8. Kim A, Banevicius MA. Nicolau DP. In vivo pharmacody namic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 59: 2497-2502.
9. Hori T, Nakano M, Kimura Y et al. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 2006; 20: 91-96.
10. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother. 2009; [in press].
11. Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo anti-bacterial activities of S 4661. a new carbapenem. Antimicrob Agents Chemother 1998; 42: 94-99.
12. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agent Chemother 2004; 48: 3136 3140.
13. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report. Clin Microbiol Infort 2005; 11: 974-984.
14. Ge Y, Wikler MA, Sahm DF et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48: 1384 1396.
15. Doribax [Package insert]. Raritan NJ: Ortho-McNeil Pharmaceutical Inc; 2007.
16. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram negative bacilli with various β-lactamase resistance mechanisms. Diag Microbiol Infect Dis 2005; 59: 71-74.
17. Hoffmann H, Stürenburg E, Heesemann J et al. Prevalence of extended-spectrum β-lactamases in isolates of the Enterobacter cloacae complex from German hospitals, Clin Microbiol Infect 2006; 12: 322 330.
18. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 1313-1319.
19. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae, Nature 1965; 208-239-241.
20. Shakil S, Akram M, Khan AU. Tigecycline: a critical update .J Chemother 2008; 20: 411-419.
21. Naber K, Redman R, Kotey P, et al. Intravenous therapy with doripenem vs. levofloxacin with an option for oral stepdown therapy in the treatment of complicated urinary tract infection and pyelonephritis. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich Germany, Apr 1-4 2007. [abstract 1733-331].
22. Solomkin J, Umeh O, Jiang J, et al. Doripenem versus meropenem with an option for oral stepdown therapy in the treatment of complicated intra-abdominal infections. [poster] Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, September 17-20, 2007.
23. Lucasti C, Jasovich A, Umeh O et al. Treatment of complicated intra-abdominal infections: doripenem versus meropenem. In: 17th European Congress of Clinical Microbiology and Infectious Diseases ICC, Munich, Germany, 31 Mar - 04 Apr 2007. Abstract 1733 332.
24. Réa-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Mori Res Opin 2008; 24: 2113 2126.
25. Nakajima Y, Mizobuchi M, Nakamura M et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004; 32: 1383 1391.
26. Merchant S, Gast C, Nathwani D et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008; 30: 717-733.